MedTrace Logo

Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

NCT00987415 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2014-11-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.

Conditions

Interventions

DRUG

allopurinol

Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.

DRUG

sugar pill

Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • Eugene Braunwald, MD · Harvard University

  • Alice Mascette, MD · National Heart, Lung, and Blood Institute (NHLBI)

  • Adrian Hernandez, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987415 on ClinicalTrials.gov